Further efforts should be performed to determine if the administration of IL4 could ameliorate cancer‐induced muscle atrophy when associated to chemotherapeutic drugs and perhaps extend this treatment to other disorders where muscle precursor accumulation occurs, such as muscular dystrophies (at least in the initial phases of the disease) or myotonic dystrophies, also characterized by chronic inflammation. This evidence concerns the gene IL4 and myotonic dystrophy.